Table 2.
HRs for the incidence of SARS-CoV-2 infection and severe, critical, and fatal COVID-19
|
Natural infection versus BNT162b2 vaccination study |
Natural infection versus mRNA-1273 vaccination study |
|||
|---|---|---|---|---|
| Natural infection cohort | BNT162b2-vaccinated cohort | Natural infection cohort | mRNA-1273-vaccinated cohort | |
| Total follow-up, person-weeks | 1 985 243 | 1 921 539 | 1 374 220 | 1 338 649 |
| Incidence rate of infection, per 10 000 person-weeks | 18·1 (17·5–18·7) | 37·1 (36·2–37·9) | 16·7 (16·1–17·4) | 32·0 (31·0–33·0) |
| Unadjusted HR for SARS-CoV-2 infection | 0·48 (0·46–0·50) | 1 (ref) | 0·51 (0·49–0·54) | 1 (ref) |
| Adjusted HR for SARS-CoV-2 infection* | 0·47 (0·45–0·48) | 1 (ref) | 0·51 (0·49–0·54) | 1 (ref) |
| Unadjusted HR for severe, critical, or fatal COVID-19† | 0·25 (0·08–0·77) | 1 (ref) | 0·27 (0·06–1·32) | 1 (ref) |
| Adjusted HR for severe, critical, or fatal COVID-19*† | 0·24 (0·08–0·72) | 1 (ref) | 0·24 (0·05–1·19) | 1 (ref) |
95% CIs for HRs and incidence rate are shown in parentheses. HR=hazard ratio.
*
Cox regression analysis adjusted for sex, 10-year age group, ten nationality groups, comorbidity count (table 1), and timing of primary infection or first-dose vaccination.